date:Feb 21, 2013
year experienced continued growth in advanced forms, premixes and nutritional lipids and contributions from acquisitions, DSM said.
Companywide, DSMs EBITDA fell 16% to 1,109 million, which compared with 1,325 million in the previous fiscal year. Net profit in the fiscal year dropped 65% to 288 million, or 2.78 per share, which compared with 814 million, or 3.66 per share, in the previous fiscal year. Net sales in the fiscal year of 9,131 million marked a 1% drop from 9,048 million in the prev